Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Leung

Allergy & Immunology Denver, CO Medical Doctor

NPI 1215012950 CMS profile 1166460

1400 Jackson St, Denver, CO 80206

Open in the dashboard

General payments

$207,566

107 records reported · program years 2019–2025

Research payments

$17,486

Paid to them · 30 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,297,677 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Donald Leung of Denver, CO is reported in the CMS Open Payments database as having received $207,566 across 107 general payments and $17,486 in research payments paid to them. Separately, studies naming them as principal investigator received $3,297,677 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,322 20
2025 Research $5,100 6
2024 General $45,972 17
2024 Research $5,150 8
2023 General $64,263 21
2023 Research $4,091 10
2022 General $10,627 12
2022 Research $2,756 5
2021 General $13,870 14
2021 Research $389 1
2020 General $17,535 10
2019 General $11,975 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Leung
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Donald Leung were reported at $43,322. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Donald Leung Allergy & Immunology median Middle half National median
2019 $11,975 $594 $163–$1,512 $163
2020 $17,535 $426 $106–$1,233 $114
2021 $13,870 $638 $157–$1,708 $132
2022 $10,627 $790 $205–$1,961 $149
2023 $64,263 $852 $220–$2,147 $160
2024 $45,972 $865 $203–$2,267 $164
2025 $43,322 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $160,839 53 payments
  2. LEO Pharma Inc. $17,970 7 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $7,848 9 payments
  4. Boehringer Ingelheim International GmbH $5,672 4 payments
  5. Genentech, Inc. $3,479 3 payments
  6. Pfizer Inc. $2,833 3 payments
  7. Incyte Corporation $2,455 1 payment
  8. Janssen Research & Development, LLC $2,100 2 payments
  9. Aimmune Therapeutics, Inc. $1,875 3 payments
  10. Novartis Pharmaceuticals Corporation $1,308 1 payment
  11. Other $1,187 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $149,655 33 payments
  2. Travel and Lodging $52,371 24 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,172 5 payments
  4. Food and Beverage $2,341 41 payments
  5. Education $28 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $84,089 26 payments
  2. EUCRISA $2,723 2 payments
  3. PALFORZIA $625 1 payment
  4. Acuvue $216 9 payments
  5. Xolair $149 2 payments
  6. RINVOQ $128 5 payments
  7. CIBINQO $110 1 payment
  8. DUPIXENT Immunology And Inflammation $90 1 payment
  9. DUPIXENT Immunology $58 1 payment
  10. ProAir Digihaler $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $8,250 20 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $6,000 3 payments
  3. Regeneron Pharmaceuticals, Inc. $3,236 7 payments

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record